U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940739) titled 'A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel' on April 08.
Brief Summary: A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
Study Start Date: March 11
Study Type: INTERVENTIONAL
Condition:
Unresectable Melanoma
Metastatic Melanoma
Ocular Melanoma
Intervention:
BIOLOGICAL: IOV-3001
IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.
Recruitment Status: R...